Gsa Capital Partners LLP Aveo Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.61 - $8.72 $20,907 - $27,581	-3,163 Reduced 9.47%	30,247 $249,000
Q2 2022 Aug 09, 2022	BUY	$3.51 - $6.67 $117,269 - $222,844	33,410 New	33,410 $219,000
Q4 2021 Feb 14, 2022	SELL	$4.69 - $7.4 $165,238 - $260,716	-35,232 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$5.12 - $6.89 $180,387 - $242,748	35,232 New	35,232 $218,000
Q3 2020 Nov 06, 2020	SELL	$4.16 - $6.26 $139,139 - $209,378	-33,447 Closed	0 $0
Q2 2020 Aug 11, 2020	SELL	$3.47 - $9.99 $199,611 - $574,674	-57,525 Reduced 63.23%	33,447 $172,000
Q1 2020 May 12, 2020	BUY	$2.6 - $6.9 $236,527 - $627,706	90,972 New	90,972 $329,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.